HEALTHCARE SOLUTIONS PROVIDER
US Stock Market Top Gainers: Robinhood, AppLovin, Quantumscape lead Wall Street rally as Nasdaq, S&P hit record highs
US stocks surged today, with Nasdaq and S&P 500 hitting record highs while the Dow remained steady. Wall Street saw strong buying in tech, AI, and energy sectors, led by Robinhood (HOOD), AppLovin (APP), and Quantumscape (QS).
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 25%
Are you looking at the Nifty to figure out whether to be bullish or bearish? If yes, cast your eye back to the day last year when the big correction started. Did all stocks start falling only after September 26, 2024, the day the indices peaked? No. Several stocks across segments began declining much before that day. The lesson: Focus on companies where the broader picture of growth is intact. And let the Nifty do what it is doing. Focus on the management, a key driver of earnings. Also, because GST rationalisation will likely impact earnings in a positive way, it is probably a good time to keep scepticism aside, but with conditions.
Pharma stocks: Moving from ‘What if’ to ‘Maybe not’. 8 pharma stocks, 3 with upside potential above 22%; others not so high, but…
There are two ways to look at the hope which the street is reflecting when it comes to a possible India-US tariff deal. One, it will bring down the tariffs (raised recently) on a number of products. Two, it removes the fear hanging over some companies and sectors that they may be put on the tariff list if the situation is not resolved. Now, which is the sector where the fear of a possible tariff hike is most palpable? The answer is pharma. The reason it has not been tariffed by President Trump is that any additional duty will mean higher medicine costs in the US. And it will lead to higher inflation. But then you don't know what he might do. So, there is an element of “what if” at the moment, and getting that removed is good enough.
ChrysCapital, InCred invest in Amber subsidiary ILJIN Electronics
ILJIN Electronics India, an Amber Group subsidiary, secured ₹1,200 Crore in funding from ChrysCapital and InCred Growth Partners. ChrysCapital leads with ₹1,100 crore, enabling ILJIN to expand operations, enhance manufacturing, and pursue strategic acquisitions. ILJIN reported strong FY25 revenues of ₹2,194 crore, driven by a 52% CAGR from FY22-25, and is expanding into Battery Energy Storage Systems and industrial automation.
Dividend yield: Stock traders can use it differently to distinguish between the probability & possibility of making money
Dividend yield is not just an investor’s tool. At certain points in the market, it becomes just as relevant – sometimes even more so – for traders. Yes, traders. Now, why would dividend yield, of all things, act like a support line? The explanation lies in market memory and psychology. Around a certain level of dividend yield, value-oriented funds begin to step in because the price suddenly offers the comfort of an income stock. Momentum traders see valuation support and a floor building underneath the price. Options desks recalibrate, as downside looks limited and covered calls turn attractive. Each group is reacting to its own cues, but collectively they create the reflexive bounce that turns weakness into opportunity for traders.
Reusable water bottles aren’t always healthy; here’s how to clean it and protect yourself from mold
Reusable water bottles, a popular and eco-conscious choice, can harbor harmful bacteria and mold if not properly cleaned. Experts warn that moisture and organic matter create breeding grounds for these microbes, potentially causing respiratory issues and allergic reactions. Regular cleaning with hot water, soap, and sanitizers is crucial to mitigate these risks and maintain a safe hydration routine.
- Go To Page 1
Beat screen fatigue fast: This 20-second trick every optometrist recommends
With screens being an important part in work, study, and leisure, many people suffer from digital eye strain, which can result in dryness, fatigue, blurred vision, and headaches. Reduced blinking and extended near-focus are major factors contributing to it, while exposure to blue light can further disrupt sleep patterns and intensify discomfort. Eye specialists suggest simple methods , like the 20-20-20 rule to protect eye health.
For wealth creation, focus on ‘Irrespective of & Despite Trump’: 7 mid-caps from different sectors with upside potential of up to 42%
Friday evening. We are not using the exact words, but the essence of what President Trump said was: India and Russia have fallen into China’s hands. Saturday evening. A 180-degree turn. I have a great relationship with PM Modi and I am only upset because India is buying too much Russian oil, Trump said. So, if you had bearish thoughts on Friday, Saturday would have seen you thinking bullish. It is Sunday and one does not quite know what to expect today. We are dealing with a president whose statements seem to depend on which side of the bed he got up from. The difference is that this time we have an Indian reaction appreciating the positive statements. So, be hopeful but cautious. In this administration, nothing positive is done till it is done.
Stock picks of the week: 6 stocks with consistent score improvement and return potential of up to 35% in 1 year
For the next few months, before you take any buy-sell decision on the stock market, ask yourself this question. How is the Nifty’s movement impacting the bottom line of a company whose stock you are planning to buy-sell? The answer will help you avoid making wrong decisions. Now, why is there a high probability of making a wrong decision? Simple: News flows and statements from the US administration will create confusion in the short term. So, check out the stock you are targeting carefully.
Meghalaya inks MoU with Japan’s Asean One to train and place youth abroad
The Meghalaya government and Asean One Co. Ltd., Japan, have signed an MoU to create international career opportunities for Meghalaya's youth. This partnership, a result of Chief Minister's visit to Japan, will focus on training and placing youth in healthcare, IT, and other sectors, starting with 500 candidates and scaling to 5,000 over five years.
Trump’s tariff rhetoric sets backdrop for India’s pharma confidence at iPHEX 2025
Alongside the exhibition, the Global Regulatory Conclave, held with CDSCO and Pharmexcil, spotlights reliance practices, pharmacopoeia convergence, and regulatory pathways to reinforce India’s standing in global pharma.
Trump’s tariff pains, Modi’s GST relief: Govt gives a reform armour to every Indian
India rolls out GST 2.0 reforms to boost domestic consumption and shield the economy from the impact of US tariffs. The revamped GST structure simplifies tax slabs and lowers rates on essential goods and services, putting more money in the hands of households and businesses. Experts say the reforms could give a meaningful lift to GDP, while rising consumer confidence across urban and rural India signals stronger spending ahead.
AI-led healthcare startup Reveal HealthTech raises $7.2 million in round led by Leo Capital
Sanos Capital participated in the funding round. Reveal was incubated by W Health Ventures, which supports startups in the US and India that focus on improving care delivery by leveraging technology. The US-headquartered startup will use the funds to scale its flagship products — BioCanvas, which applies multimodal AI to accelerate clinical trial recruitment, and Prism AI, a workflow automation platform.
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analysts
In the last three trading sessions, the one thing clearly favouring the bulls was market breadth, especially in the mid-cap segment. A part of this optimism stems from the street’s expectation that the GST rate rationalisation will be implemented soon. Now, given that it may be implemented as soon as September 22, it probably takes away the fear that this festive season will suffer due to delayed purchases. So, in all probability, some select consumer stocks will get more attention in the coming days.
Amanta Healthcare IPO subscribed 12.40 times on Day 2; GMP at 12% — Should you bid? Check key details
Amanta Healthcare's Rs 126 crore IPO witnessed strong investor demand, subscribing 12.40 times on its second day, driven by retail investors. The IPO, closing on September 3, sees shares trading at a 12% grey market premium. The Ahmedabad-based pharmaceutical firm plans to use IPO proceeds for expansion. Investor4Edu recommends subscribing, citing growth potential in sterile pharmaceuticals.
8 money mistakes that can ruin your retirement and how to avoid them
Retirement needs careful financial planning. Even small mistakes can diminish savings. A withdrawal plan is crucial. Avoid locking funds in annuities. Equities should be part of the portfolio. Medical insurance is essential. Estate planning is important for seamless asset transition. Illiquid assets pose risks. Clear debts before retirement for financial stability.
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of more than 22%
Here’s the thumb rule: Always make a distinction between what is happening to the stock price and what is happening to the fundamentals of a company or sector. There are times, however, when this is even more important. At this point of time, the risk of more headwinds for the economy are high. But did the movement of the market on Monday give you that feeling? So, a couple of things: If you are putting money into the market, make sure it is not money you need in a hurry. Also: Focus on a few businesses and even fewer stocks; and ignore the noise on the street.
Amanta Healthcare IPO opens for subscription; GMP at 22%. Should you bid?
IPO GMP: Amanta Healthcare's Rs 126 crore IPO opened on Monday, with a price band of Rs 120-126 per share. The Ahmedabad-based pharma company will use the funds to expand its manufacturing capabilities. Investor4Edu recommends subscribing, citing the company's strong position in the growing sterile liquid pharmaceuticals market. The IPO is valued at 47x post-issue FY25 earnings, with listing expected on September 8.
ET Startup Awards 2025 | Top Innovator: Qure.ai bridges diagnostic gap
Founded in Mumbai in 2016 by Prashant Warier, Qure.ai’s mission is to make healthcare more affordable and accessible through AI-powered diagnostic tools. Its products assist clinicians in detecting conditions such as tuberculosis, lung cancer, and pulmonary disorders, speeding up diagnoses, and enabling more efficient treatment plans, particularly in resource-constrained settings.
ET Startup Awards 2025 | Urban Company brings it home, bags top honours
The 10-member jury, chaired by Amitabh Kant, India’s former G20 Sherpa, recognised Urban Company’s scale, category leadership and ability to create a trusted brand in one of India’s most unorganised and toughest sectors. Urban Company, founded by Abhiraj Singh Bhal, Varun Khaitan and Raghav Chandra in 2014, joins a list of eminent winners of the top prize, including Lenskart, Zomato, OfBusiness, Razorpay, Delhivery and Swiggy.
ET Startup Awards 2025: Bootstrap Champ: Low burn and high agility take Minfy to cloud nine
Founded in 2010 by brothers Vijay and Vivek Jain, Minfy began with the insight that the cloud would become the foundation of enterprise technology.
Dividend yield: There is more to it than meets the eye, both for investors & traders, especially in volatile times. 11 stocks to look at
These days the Nifty and Sensex tend to slip into volatility every second week. Given the tariff situation, we don't know for how long this will continue. To deal with volatility, it would be a good idea to use a mix of conventional and unconventional methods. This will ensure that, if the market stays under pressure and stocks do not create wealth, they at least generate income. Now, what is the income stocks generate? It is the dividend you get by holding a stock. It is different from income which trading in stocks generates. So, don't confuse the two. Dividend yield can help both investors and traders. In the case of traders, it will require some hard work. But who said making money in the market is easy?
Pharma sector: Reasons to look at it beyond the tariff exemption. 7 pharma stocks with an upside potential of up to 43%
Along with semiconductors, electronics and IT, pharma is another sector exempt from the Trump tariffs. Still, as the broader indices declined after the imposition of two rounds of tariffs, with the latest of 25% kicking in on August 27, pharma stocks have also seen drops over the past month. Now, is this an opportunity, given that the sector is exempt? Perhaps. Because, one does not know what President Trump may do in the future. But the pharma sector merits a closer look for reasons other than being exempt from tariffs. For, in the last 20 years, companies in this sector, because of some inherent advantages, have been able to deliver. And going forward, there is a high probability that these tailwinds will increase.
For long-term investors: Trump or tariffs are problems with shelf life; focus on business. 10 large-caps with upside potential of up to 24%
Volatility is back on the front page, and you may hear more about it next week. Fresh tariff headlines from the US, a bout of valuation anxiety at home, and the usual chorus of “this time is different” have turned the screens red and the mood bearish. If you’ve been investing in the stock market for more than a few monsoons, though, you’ve watched this movie before. But investing is not like movies which get over in three hours max. Investing is about the underlying value of good businesses which do not get distorted by statements or headline hoggers.
How Ambani plans to milk the Kamdhenu cow
Reliance Industries is boosting its focus on artificial intelligence. Mukesh Ambani announced Reliance Intelligence, a new unit for AI. Partnerships with Meta and Google are central to this push. Reliance will build AI-ready data centers. Google and Reliance are establishing a Jamnagar Cloud region. Meta and Reliance will deliver open-source AI models to Indian businesses.
Reliance AGM 2025: Mukesh Ambani launches Reliance Intelligence, partners with Google, Meta to drive India’s AI revolution
Mukesh Ambani announced the launch of Reliance Intelligence, a wholly-owned subsidiary, to boost India's AI capabilities. The initiative focuses on building AI infrastructure, forging global partnerships, and delivering AI services for consumers and enterprises. Reliance aims to establish itself as a deep-tech AI hub, driving national growth and global competitiveness through this venture.
India, Africa to work to double bilateral trade by 2030: Piyush Goyal
Union Minister of Commerce and Industry Piyush Goyal stated that India and Africa will collaborate to double bilateral trade by 2030, with a focus on value addition, technology-driven farming, renewable energy, and healthcare. While addressing the valedictory session of the 20th CII India-Africa Business Conclave in New Delhi, Goyal stated, "Together, we can move from raw material exports to value-added production for global markets."
Reliance to set up 'Reliance Intelligence': AI for everyone, everywhere
Reliance Intelligence will build gigawatt-scale, AI-ready data centres, powered by green energy and engineered for training and inference at a national scale, he said at the company's AGM.
Draft of Delhi Startup Policy 2025 released: Manjinder Singh Sirsa
The Delhi government unveiled its draft Startup Policy 2025, anchored by a Rs 200 crore venture capital fund to back 5,000 startups over the next decade.
Load More
